Recently, the PD-1 checkpoint inhibitors nivolumab and pembrolizumab that block the binding of the PD-1 ligands PD-L1 and PD-L2 have gained regulatory approval for the treatment of recurrent and metastasized HNSCC. Here, PDCD1LG2 is linked to head and neck squamous cell carcinoma.